Skip to main content
. 2021 Jan 15;39(17):1865–1877. doi: 10.1200/JCO.20.01086

FIG 3.

FIG 3.

Key transplant outcomes. (A) 7/8 Cohort, cumulative incidence of nonrelapse mortality (NRM). Number of patients at risk and censored are listed below the graph. (B) 8/8 Cohort, cumulative incidence of NRM. Number of patients at risk and censored are listed below the graph. (C) 7/8 Cohort, cumulative incidence of relapse-free survival (RFS). Number of patients at risk and censored are listed below the graph. (D) 8/8 Cohort, cumulative incidence of RFS. Number of patients at risk and censored are listed below the graph. (E) 7/8 Cohort, cumulative incidence of. Number of patients at risk and censored are listed below the graph. (F) 8/8 Cohort, cumulative incidence of OS. Number of patients at risk and censored are listed below the graph. 7/8 Cohort: Blue: CIBMTR control cohort. Solid red: 7/8 abatacept cohort, matched to the CIBMTR controls. Dashed red: 7/8 intention-to-treat (ITT) cohort. P values represent comparison of 7/8 abatacept cohort and CIBMTR control cohort. 8/8 Cohort: Blue: Placebo. Red: Abatacept. ABA, abatacept; ATG, anti-thymocyte globulin; CIBMTR, Center for International Blood and Marrow Transplant Research; OS, overall survival.